CBD May Reduce the Ability of Immune Cells to Kill Cancer That Displays a Specific Stress Protein

CBD treatment significantly reduced the release of interferon-gamma and granzyme B from activated NK cells, lowered Hsp70 expression on tumor surfaces, and decreased NK cell killing of high-Hsp70-expressing cancer cells. Low-Hsp70 tumors were unaffected.

In vitro study examining CBD's effects on NK cells stimulated with TKD Hsp70 peptide and IL-2, and on HCT116 colorectal cancer cells with different levels of membrane Hsp70 expression. NK cell receptor expression, cytokine release, and cytotoxicity were measured.

Many cancer patients use CBD for symptom management during treatment. This study raises a specific, mechanistic concern: CBD might interfere with NK cell-based immune responses against tumors that display the stress protein Hsp70, potentially undermining certain immunotherapy approaches.

As CBD becomes widely used alongside conventional cancer therapies, understanding where it helps and where it may hinder becomes critical. The Hsp70-NK cell axis is a target of emerging cancer immunotherapies, and CBD's interference with this specific pathway deserves attention in clinical settings.

In vitro study using cell lines, which may not reflect the complexity of CBD-immune interactions in living organisms. CBD concentrations used may not match what patients actually achieve in tissue. Only one type of cancer cell line was examined.